UNDIFFERENTIATED PLEOMORPHIC SARCOMA : PROGNOSTIC FACTORS IN 42 EXTREMITY CASES
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ATHA COMUNICACAO & EDITORA
Citação
ACTA ORTOPEDICA BRASILEIRA, v.31, n.2, article ID e265942, 5p, 2023
Resumo
Introduction: Soft tissue undifferentiated pleomorphic sarcoma (UPS) in extremities is considered a rare neoplasm, corresponding to 5% of soft tissue sarcomas (STS) today. The objective was to evaluate prognostic factors related to death, local recurrence (LR), and impact on survival rates. Methods: A retrospective study including 42 patients with UPS in extremities treated surgically in a single center. Comparisons were made between demographic data, characteristics of the neoplasia, and treatment. Between the variables with statistical significance, logistic regression analysis was used. Survival rates were evaluated using Kaplan-Meier plots. To compare the effect of variables on survival rates, the Log-Rank test was used. Results: Age group of patients was from 25 to 85 years (mean 58 years), with a mean follow-up of 29.6 months. The variables with the highest effect on survival rates were sizes larger than 15 cm (T4) with p = 0.01, presence of metastatic lesions, and prognostic stage IV according to the American Joint Committee of Cancer (AJCC) with p < 0.001. The mean survival was 25.9 months. Metastasis and stage IV of AJCC were associated with a reduction in patient survival (17.8 months) with Log-Rank test p < 0.001. Conclusion: The main factors of poor prognosis related to mortality and reduction of survival of UPS in extremities were metastatic lesions and stage IV of AJCC. Level of Evidence III, Retrospective Study.
Palavras-chave
Histiocytoma, Malignant Fibrous, Sarcoma, Prognosis, Recurrence, Death, Survival, Histiocitoma Fibroso Maligno, Sarcoma, Morte
Referências
- Camargo OP, 2012, CLINICA ORTOPEDICA
- Enneking WF, 2003, CLIN ORTHOP RELAT R, P4, DOI 10.1097/01.blo.0000093891.12372.0f
- Fletcher CD, 2013, WHO CLASSIFICATION T, DOI 10.1155/2014/902620
- FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P213, DOI 10.1097/00000478-199203000-00001
- Gibbs JF, 2001, CANCER INVEST, V19, P23, DOI 10.1081/CNV-100000071
- Hermanek P, 1999, J CLIN EPIDEMIOL, V52, P371, DOI 10.1016/S0895-4356(98)00177-2
- KAUFFMAN SL, 1961, CANCER, V14, P469, DOI 10.1002/1097-0142(199005/06)14:3<469::AID-CNCR2820140304>3.0.CO;2-Q
- KEARNEY MM, 1980, CANCER, V45, P167, DOI 10.1002/1097-0142(19800101)45:1<167::AID-CNCR2820450127>3.0.CO;2-8
- KEMPSON RL, 1972, CANCER, V29, P961, DOI 10.1002/1097-0142(197204)29:4<961::AID-CNCR2820290443>3.0.CO;2-A
- Maretty-Nielsen Katja, 2014, Dan Med J, V61, pB4957
- MARKHEDE G, 1982, CANCER, V48, P1721, DOI 10.1002/1097-0142(19820415)49:8<1721::AID-CNCR2820490832>3.0.CO;2-X
- Ozcelik M, 2016, TUMOR BIOL, V37, P5231, DOI 10.1007/s13277-015-4359-1
- OZZELLO L, 1963, CANCER-AM CANCER SOC, V16, P331, DOI 10.1002/1097-0142(196303)16:3<331::AID-CNCR2820160307>3.0.CO;2-F
- PEZZI CM, 1992, CANCER, V69, P2098, DOI 10.1002/1097-0142(19920415)69:8<2098::AID-CNCR2820690815>3.0.CO;2-9
- Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679
- Raut CP, 2018, AJCC CANC STAGING MA, V8th, P517
- TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108
- Vodanovich DA, 2019, ANZ J SURG, V89, P1045, DOI 10.1111/ans.15348
- WEISS SW, 1978, CANCER-AM CANCER SOC, V41, P2250, DOI 10.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-W